Real world outcomes support the benefits of psychedelic therapy for severe depression

The Crisis of Treatment-Resistant Mental Health Conditions The global mental health landscape has reached a critical juncture where traditional pharmacotherapy often falls short. For decades, Selective Serotonin Reuptake Inhibitors (SSRIs)…

LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial

The therapeutic landscape for mental health is undergoing a significant shift as researchers revisit substances once relegated to the fringes of medicine. A recent pilot study conducted by researchers at…

Trajectories of Psychological Outcomes During the 2024 U.S. Presidential Election

The 2024 United States presidential election served as a profound catalyst for psychological shifts within the American electorate, according to a comprehensive 20-week longitudinal study. Published in the journal Personality…

Influence of Active Production Versus Passive Consumption of Podcasts on Medical Students’ Learning Outcomes

A team of researchers at a prominent German medical school recently conducted an experimental study to determine whether the act of creating digital media, specifically podcasts, provides a superior educational…

Longitudinal study finds procrastination declines with age but still shapes major life outcomes over nearly two decades

A Longitudinal Perspective on Chronic Delay For decades, psychological research into procrastination has been characterized by its focus on short-term outcomes, particularly within the confines of academic environments. Most studies…

GLP-1 Medications Show Significant Promise in Improving Mental Health Outcomes, New Large-Scale Study Reveals

New research has unveiled a compelling link between GLP-1 receptor agonists, commonly prescribed for type 2 diabetes and obesity, and significant improvements in mental health. A comprehensive study conducted by…

GLP-1 Medications Show Promising Links to Improved Mental Health Outcomes in Large-Scale Study

New research indicates that glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications increasingly recognized for their efficacy in managing type 2 diabetes and obesity, may also exert significant positive…